10.6084/m9.figshare.6025667.v1 Kate McKeage Kate McKeage Katherine Lyseng-Williamson Katherine Lyseng-Williamson Poractant alfa in respiratory distress syndrome in preterm infants: a guide to its use Adis Journals 2018 Poractant alfa Curosurf® Respiratory Distress Syndrome RDS Adis Drug Review 2018-03-25 22:09:43 Online resource https://adisjournals.figshare.com/articles/online_resource/Poractant_alfa_in_respiratory_distress_syndrome_in_preterm_infants_a_guide_to_its_use/6025667 <div>Compliance with ethical standards</div><div><br></div><div><i>Funding:</i> The preparation of this review was not supported by any external funding.</div><div><br></div><div><i>Conflicts of interest:</i> K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.</div><div> </div><div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a>.</div><div><br></div><div>Abstract</div><div><br></div><div>Poractant alfa (Curosurf®) is a natural, porcine-derived surfactant that is well established as an effective and generally well-tolerated agent in the treatment of respiratory distress syndrome (RDS) in preterm infants. The efficacy of poractant alfa in RDS is better than that of early-generation synthetic surfactants, and limited data are available regarding its efficacy versus new-generation synthetic agents. Poractant alfa 200 mg/kg is more effective than poractant alfa 100 mg/kg or bovine-derived beractant 100 mg/kg. Techniques for administering poractant alfa include via an endotracheal tube or less invasive techniques [e.g. less invasive surfactant administration (LISA)] performed during non-invasive ventilation of spontaneously breathing infants via nasal continuous positive airway pressure (CPAP). Administration of poractant alfa 200 mg/kg in early rescue [i.e. fraction of inspired oxygen (FiO2) ≥ 0.3] via LISA is associated with increased successful management on continuous positive airway pressure, as well as reductions in the incidence of bronchopulmonary dysplasia (BPD) and death/BPD. Access to the full article can be found <b><a href="https://link.springer.com/article/10.1007/s40267-017-0437-3">here</a>.</b></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017</div>